Our finding that AHR is a transcriptional regulator of astrocytic Ptn expression is further supported by reduced serum levels of AHR-agonists in MS patients during remission and primary progressive MS (PPMS), matching our observations of diminished astrocyte-derived PTN expression during late-stage EAE (44, 45). This evidence concerns the gene AHR and myeloid sarcoma.